Trials / Completed
CompletedNCT02323893
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Healthy Humans
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- CellSight Technologies, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to visualize biodistribution of a PET tracer called \[18F\]F-AraG through time in healthy human volunteers.
Detailed description
A positron emission tomography (PET) imaging tracer will be intravenously injected into healthy human volunteers who provide informed consent. Following injection of this tracer each volunteer will have four whole-body PET scans inside a PET scanner to obtain images of tracer biodistribution at four different time points. This will allow studying the kinetics of the tracer as well analysis of tracer dosimetry. Safety of the tracer will also be analyzed in each volunteer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]F-AraG |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
- First posted
- 2014-12-24
- Last updated
- 2018-05-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02323893. Inclusion in this directory is not an endorsement.